# The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

> **NCT03192644** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 162 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TAI
- **PROCEDURE:** TACE
- **DRUG:** epidoxorubicin and cisplatin and lipiodol
- **DRUG:** mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

## Key facts

- **NCT ID:** NCT03192644
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192644, "The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03192644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*